After Hours Gainer
BTAI Bioxcel Therapeutics5.24+0.08+1.6%
After Hours:6.24+1.00 (+19.1%)
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
Globe NewswireTue, 26-Aug 4:00 PM
After Hours:6.10+0.86 (+16.4%)
BTAI Bioxcel Therapeutics3.67+0.16 (+4.6%)
BTAI Bioxcel Therapeutics3.56-0.03 (-0.8%)
BTAI Bioxcel Therapeutics3.29+0.19 (+6.1%)